Asensus Surgical (formerly known as TransEnterix)

136 articles with Asensus Surgical (formerly known as TransEnterix)

• Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2020

  3/11/2021

  Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, announced its operating and financial results for the fourth quarter and full-year 2020.

• Asensus Surgical Announces Finalization of Name and Ticker Symbol Change

  3/5/2021

  Asensus Surgical , Inc. (formerly TransEnterix, Inc.) (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the formal completion of its previously announced name and ticker symbol change.

• Asensus Surgical Announces FDA Clearance in General Surgery

  3/3/2021

  Asensus Surgical , Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System

• Asensus Surgical to Present at the H.C. Wainwright Virtual Global Life Sciences Conference

  3/1/2021

  Asensus Surgical, Inc. announced that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference taking place March 9 and March 10, 2021.

• TransEnterix Announces Name Change to Asensus Surgical and Introduces a New Category of Surgery, Performance-Guided Surgery

  2/23/2021

  TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will change its corporate name to Asensus Surgical, Inc.

• TransEnterix to Host Virtual Investor Day on February 23, 2021

  2/10/2021

  TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will host a virtual Investor Day on February 23, 2021, beginning at 11:00am Eastern Time.

• TransEnterix Announces Closing of $79.6 Million Bought Deal Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

  2/1/2021

  TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the closing of its previously announced underwritten public offering of its common stock.

• TransEnterix Announces $25.0 Million Bought Deal Offering of Common Stock

  1/26/2021

  TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co.

• TransEnterix Announces Closing of $31.25 Million Registered Direct Offering of Common Stock

  1/14/2021

  TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the closing of its previously announced registered direct offering of 25,000,000 shares of its common stock.

• TransEnterix Announces $31.25 Million Registered Direct Offering of Common Stock

  1/12/2021

  TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has entered into securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering of 25,000,000 shares of its common stock at a purchase price of $1.25 per share for gross proceeds of $31.25 million.

• TransEnterix to Participate in Two Upcoming Virtual Healthcare Conferences

  1/4/2021

  TransEnterix, Inc. (NYSE American: TRXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will present at two upcoming virtual investor conferences:

• TransEnterix Announces Southern Surgical Hospital to Initiate a Senhance® Digital Laparoscopic Program

  12/17/2020

  TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Southern Surgical Hospital has entered into an agreement to lease and utilize a Senhance® Surgical System.

• TransEnterix to Present at the Stifel 2020 Virtual Healthcare Conference

  11/3/2020

  TransEnterix, Inc. (NYSE American:TRXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will present at the Stifel 2020 Virtual Healthcare Conference.

• TransEnterix Announces First Pediatric Surgical Cases with Senhance® Surgical System

  10/13/2020

  Pediatric Patients Successfully Treated Utilizing 3mm Instruments on Digital Laparoscopy Platform

• TransEnterix Announces Toshima Hospital in Japan to Initiate a Senhance® Digital Laparoscopy Program

  10/7/2020

  TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced that the Toshima Hospital of the Tokyo Metropolitan Health and Hospitals Corporation has entered into an agreement to lease and utilize a Senhance® Surgical System.

• TransEnterix Announces Establishment of Japanese Training Center for Senhance Surgical System

  9/14/2020

  TransEnterix, Inc. announced that it established the first training center for the Senhance® Surgical System in the Asia-Pacific region in Japan at the Saitama Medical University International Medical Center in the Greater Tokyo Area.

• TransEnterix to Present at the H. C. Wainwright 22nd Annual Global Investment Conference

  9/8/2020

  TransEnterix, Inc. announced that Anthony Fernando, President and Chief Executive Officer and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will present at the H. C. Wainwright 22nd Annual Global Investment Conference.

• TransEnterix Announces New Employment Inducement Grant

  8/25/2020

  TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that in connection with the appointment of Shameze Rampertab as the Company’s Executive Vice President and Chief Financial Officer effective August 24, 2020,

• TransEnterix, Inc. Reports Operating and Financial Results for the Second Quarter 2020

  8/5/2020

  TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter of 2020.

• TransEnterix Announces Submission of General Surgery Expansion in the US

  8/4/2020

  TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced that it has submitted an indications filing to the FDA to expand General Surgery usage of the Senhance Surgical System.